ALXN1920

Protein / enzyme therapeutic

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Primary Membranous Nephropathy
NCT07157787 · Alexion Pharmaceuticals, Inc.
2025-09-19 – 2027-07-09 · Primary Membranous Nephropathy
What this study did
Phase 1 (1)
Other / comorbidity
NCT05751642 · Alexion Pharmaceuticals, Inc.
2023-04-19 – 2023-12-04 · Healthy Participants
What this study did

Competitive landscape

This drug's own stage for Primary Membranous Nephropathy: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ALXN1920: this drugPhase 2Protein / enzyme therapeuticComplement factor Hnot yet gradedNo reviewed efficacy summary in this indication
ObinutuzumabApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Obinutuzumab Beta (Bejescin)Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
PovetaciceptPhase 2/3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
BudoprutugPhase 2Monoclonal antibodyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ALXN1920 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
Phase 2Primary Membranous NephropathyRecruiting
Est. primary completion 2027-07-02 · NCT07157787 · CT.gov ↗
What to watch

See the full readout calendar ↗